How big is the out-of-hospital market where multinational pharmaceutical companies are coding?

"Pharmaceutical Network Market Analysis" In recent years, under the influence of pharmaceutical policies such as zero-rate pharmaceutical products, controlling the proportion of drugs, and purchasing volume, the decline in drug prices has become a major trend.
this is a big shock for pharmaceutical companies, especially multinational pharmaceutical companies, many original research enterprises plan to abandon the hospital market, will focus on the out-of-hospital market.
, multinational drug companies, including Pfizer, Mercedon and Roche, have increased their market investment in retail pharmacies, and Mercedon has even set up a dedicated retail pharmacy development team.
in the pharmaceutical company plus code layout behind, obviously the off-site market is full of expectations.
, but in reality, the size of the off-court market space is still a question.
people pointed out the current development bottleneck of the off-hospital market, including: the out-of-hospital market volume is small, the retail industry bargaining power is enhanced, drug price increase is limited and so on.
, in terms of out-of-hospital market volume, the data show that in 2018, the out-of-hospital market for prescription drugs accounted for about 20%, compared with 80% of the in-hospital market there is a large gap.
, in fact, multinational pharmaceutical companies layout out-of-hospital market, is not to see the potential of the out-of-hospital market, it is a helpless move to fall.
, especially under the normalization of collection, drug decline has become a major trend, for multinational pharmaceutical companies is a big impact.
in terms of bargaining power, under the influence of the collection policy, the original drug research is accelerating the transfer from the hospital to the pharmacy, the willingness and strength to set up in the pharmacy significantly increased.
, with the increased concentration of the retail industry in recent years, and the bargaining power of prescription drug companies gradually increased, the profits of multinational pharmaceutical companies will become more obvious.
also in the drug price increase, in June this year, Zhejiang Medical Insurance Bureau issued a plan to point retail pharmacies medical insurance drug payment standards unified according to the medical institutions pay standards floating 15%.
this figure means a 15 per cent cap on drug price increases in pharmacies, which the industry believes is limited or pushed away although the current unseeded product is not subject to this policy.
the outside market bottleneck obviously exists, but its development space is still generally favored by the industry.
China is the world's second largest pharmaceutical market, in the health care control fees, consistent evaluation, two-vote system, 4-7 belt procurement and a series of new health care reform, industry changes will accelerate, development will accelerate.
, on the other hand, public hospitals abolished the drug charge, the drug from the hospital's income item to the cost item, the public hospital operating drug power decreased.
the other hand, after the introduction of the procurement policy, the profit margin of pharmaceutical enterprises to enter the hospital has dropped significantly, and new out-of-hospital markets need to be sought to supplement prices.
china's drug retail market grew steadily from 2015 to 2019, with an average compound annual growth rate (CAGR) of 8.0 per cent, compared with 6.1 per cent for the drug market, according to data released last week.
with a series of good policies to further land, the industry is expected to further improve the growth rate of the off-court market.
, industry analysts pointed out that with the aging of China's population, as well as the "three-doctor linkage" medical reform, medicine gradually landed separately, prescription outflow has become the trend.
According to market research institutions forecast that by 2020, China's total prescription drug market size can reach 1890 billion yuan, hospital prescription outflow accounted for about 1/5 of the total prescription volume, China's prescription outflow market size will be close to 400 billion yuan, and the retail market for prescription drugs will be more than 150 billion yuan.